Kotak Mid cap Fund
The scheme seeks to generate long-term capital appreciation from a portfolio of equity and equity related securities, by investing predominantly in mid companies.
Growthvine rating: 4/5 — ranked #8 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹135.88 (as of 2026-10-16) |
|---|
| AUM | ₹71,256 Cr |
|---|
| Expense ratio | 1.17% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Atul Bhole |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 14.14% |
|---|
| Sharpe ratio | 0.52 |
|---|
| Standard deviation | 18.52% |
|---|
| Max drawdown | −72.00% |
|---|
| Alpha | 1.41 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 90.1% of NIFTY Midcap 150's upside and 85.2% of its downside.
Market cap allocation
| Large cap | 13.8% |
|---|
| Mid cap | 67.3% |
|---|
| Small cap | 19.0% |
|---|
Concentration
| Top 5 holdings | 15.4% |
|---|
| Top 10 holdings | 27.8% |
|---|
| Total holdings | 74 |
|---|
| Index overlap | 29.4% |
|---|
| Active share | 70.6% |
|---|
Top holdings
- Ipca Laboratories Ltd. — 3.6%
- Fortis Healthcare Ltd — 3.5%
- Vishal Mega Mart Limited — 3.0%
- Triparty Repo — 2.8%
- L&T Finance Limited — 2.7%
- Federal Bank Ltd. — 2.6%
- Mphasis Limited — 2.6%
- GE Vernova T&D India Limited — 2.5%
- KEI Industries Ltd. — 2.5%
- Dixon Technologies (India) Limited — 2.4%
Top sectors
- Banking & Financial — 13.1%
- Finance & Investments — 10.1%
- Pharma & Biotech — 9.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −0.5% | Q3 | #20 of 31 |
| 2025 | 1.8% | Q2 | #15 of 29 |
| 2024 | 33.6% | Q1 (Top) | #6 of 29 |
| 2023 | 31.5% | Q4 (Bottom) | #25 of 28 |
| 2022 | 5.1% | Q1 (Top) | #6 of 22 |